Form S-3 - Registration statement under Securities Act of 1933:
SEC Accession No. 0001641172-25-002793
Filing Date
2025-04-04
Accepted
2025-04-04 16:46:02
Documents
10

Document Format Files

Seq Description Document Type Size
1 forms-3.htm S-3 264705
2 ex5-1.htm EX-5.1 13367
3 ex23-1.htm EX-23.1 4410
4 ex107.htm EX-FILING FEES 12690
5 image_001.jpg GRAPHIC 5764
6 image_002.jpg GRAPHIC 5764
7 ex5-1_001.jpg GRAPHIC 27643
8 ex5-1_002.jpg GRAPHIC 25716
9 ex23-1_001.jpg GRAPHIC 18179
10 ex23-1_002.jpg GRAPHIC 5617
  Complete submission text file 0001641172-25-002793.txt   419109
Mailing Address 217 W. MAIN STREET SOMERVILLE NJ 08876
Business Address 217 W. MAIN STREET SOMERVILLE NJ 08876 908-370-5102
ZyVersa Therapeutics, Inc. (Filer) CIK: 0001859007 (see all company filings)

EIN.: 862685744 | State of Incorp.: DE | Fiscal Year End: 1231
Type: S-3 | Act: 33 | File No.: 333-286396 | Film No.: 25815515
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)